Yousif Capital Management LLC Sells 463 Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH)

Yousif Capital Management LLC trimmed its holdings in Prestige Consumer Healthcare Inc. (NYSE:PBH) by 2.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 19,089 shares of the company’s stock after selling 463 shares during the period. Yousif Capital Management LLC’s holdings in Prestige Consumer Healthcare were worth $1,491,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also made changes to their positions in PBH. Boston Trust Walden Corp acquired a new stake in Prestige Consumer Healthcare during the third quarter worth about $41,785,000. Allspring Global Investments Holdings LLC lifted its holdings in shares of Prestige Consumer Healthcare by 19.3% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,575,170 shares of the company’s stock worth $113,570,000 after acquiring an additional 255,045 shares during the period. Wellington Management Group LLP acquired a new stake in shares of Prestige Consumer Healthcare during the 3rd quarter worth approximately $6,342,000. Barclays PLC increased its stake in Prestige Consumer Healthcare by 346.3% in the third quarter. Barclays PLC now owns 92,444 shares of the company’s stock valued at $6,665,000 after acquiring an additional 71,730 shares during the last quarter. Finally, Congress Asset Management Co. increased its stake in Prestige Consumer Healthcare by 7.8% in the third quarter. Congress Asset Management Co. now owns 865,123 shares of the company’s stock valued at $62,375,000 after acquiring an additional 62,411 shares during the last quarter. 99.95% of the stock is currently owned by institutional investors.

Prestige Consumer Healthcare Trading Down 2.1 %

Shares of PBH stock opened at $84.18 on Thursday. Prestige Consumer Healthcare Inc. has a twelve month low of $62.35 and a twelve month high of $88.36. The stock’s fifty day simple moving average is $79.30 and its 200 day simple moving average is $75.74. The company has a quick ratio of 2.10, a current ratio of 3.68 and a debt-to-equity ratio of 0.56. The firm has a market capitalization of $4.16 billion, a P/E ratio of 19.71, a P/E/G ratio of 2.43 and a beta of 0.50.

Prestige Consumer Healthcare (NYSE:PBH) last released its quarterly earnings results on Thursday, February 6th. The company reported $1.22 earnings per share for the quarter, topping the consensus estimate of $1.18 by $0.04. Prestige Consumer Healthcare had a return on equity of 12.36% and a net margin of 19.13%. As a group, sell-side analysts predict that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current fiscal year.

Insiders Place Their Bets

In other Prestige Consumer Healthcare news, CEO Ronald M. Lombardi sold 10,875 shares of Prestige Consumer Healthcare stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $82.60, for a total transaction of $898,275.00. Following the transaction, the chief executive officer now directly owns 320,952 shares of the company’s stock, valued at approximately $26,510,635.20. The trade was a 3.28 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 1.60% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on PBH shares. Raymond James raised Prestige Consumer Healthcare to a “moderate buy” rating in a report on Thursday, December 19th. StockNews.com upgraded Prestige Consumer Healthcare from a “hold” rating to a “buy” rating in a research report on Friday, January 24th. DA Davidson lifted their target price on Prestige Consumer Healthcare from $95.00 to $104.00 and gave the company a “buy” rating in a research report on Friday, February 7th. Sidoti cut shares of Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 target price for the company. in a report on Monday, December 9th. Finally, Canaccord Genuity Group raised their price target on shares of Prestige Consumer Healthcare from $93.00 to $100.00 and gave the company a “buy” rating in a research note on Friday, February 7th. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Prestige Consumer Healthcare has a consensus rating of “Moderate Buy” and a consensus price target of $92.50.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.